18 March 2026 NMRC Advances Bacteriophage Therapy to Phase 3 Clinical Trial SILVER SPRING, Md. – Naval Medical Research Command (NMRC), in partnership with Armata Pharmaceuticals, has completed a phase 2 clinical trial on a Staphylococcus aureus (Staph A) bacteriophage therapy.The therapy, AP-SA02, used for the treatment of complicated bacteremia caused by S. aureus,...
06 June 2025 NMR&D Reaches Milestones in Six Year CDRMP Focused Program Award for Bacteriophage Therapy The landscape of bacterial health threats is ever evolving and poses a significant risk to the readiness of the U.S. military, whose members are frequently exposed to bacteria through combat injuries and deployments to overseas locations.Navy Medicine Research & Development (NMR&D) is engaged in...